Thursday, January 5, 2012
Researchers at Virginia Commonwealth University have
found that inhibiting inflammasome formation with antagonists of the membrane
receptor P2X7 could help prevent
heart failure following acute myocardial infarction.1 The findings
point to a repurposing opportunity for P2X7 antagonists that companies have in
the clinic for inflammatory indications.
from the top
Because P2X7 is necessary for the
formation of the inflammasome and the release of the downstream inflammatory
molecules, targeting the receptor could have wider anti-inflammatory effects
than targeting IL-1b.
Martz, L. SciBX 5(1);
Published online Jan. 5, 2012
1. Mezzaroma, E. et al. Proc. Natl.
Acad. Sci. USA; published online Nov.
21, 2011; doi:10.1073/pnas.1108586108
Contact: Antonio Abbate, Virginia Commonwealth University,
2. Velagaleti, R.S. et al. Circulation 118, 2057-2062
3. Kawaguchi, M. et al. Circulation 123, 594-604 (2011)
Affectis Pharmaceuticals AG, Martinsried, Germany
Brigham and Women's Hospital, Boston, Mass.
(Xetra:EVT), Hamburg, Germany
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Harvard Medical School, Boston, Mass.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden
University of Ferrara, Ferrara, Italy
Virginia Commonwealth University, Richmond, Va.